ARF-BP1/Muleは,ARF腫瘍抑制剤の重要なメディエーターである
Delin Chen1, Ning Kon, Muyang Li
1Institute for Cancer Genetics, Department of Pathology, College of Physicians and Surgeons, Columbia University, 1150 St. Nicholas Avenue, New York, New York 10032.
Cell
|July 2, 2005
まとめ
ARFの腫瘍抑制剤は,
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- バイオケミストリー バイオケミストリー
背景:
- p53の調節におけるARF腫瘍抑制剤の役割は知られているが,p53/Mdm2の独立成長抑制メカニズムについては解明が必要である.
- ARFの腫瘍抑制経路を理解することは,標的がん治療の開発に不可欠です.
研究 の 目的:
- ARF媒介による腫瘍抑制の基礎にある分子メカニズムを調査する.
- ARFと相互作用する重要な要因をインビヴォで特定し,細胞成長調節におけるそれらの役割を解明する.
主な方法:
- コイムノプレシピテーションとインビボ関連研究を用いたARF相互作用タンパク質の特定.
- ARF-BP1のユビキチンリガゼ活性とARFによるARFの抑制の評価.
- ARF-BP1不活性化後のp53-nullおよびp53ワイルド型細胞における細胞成長の分析.
- p53のARF-BP1と直接の相互作用とユビキチン化に関する調査.
主要な成果:
- Ubiquitin ligaseを含むHECTモチーフであるARF-BP1は,ARFと相互作用するタンパク質として特定されました.
- ARFはARF-BP1のユビキチンリガース活性を抑制する.
- ARF-BP1不活性化により,ARF誘導を模倣して,p53-null細胞の成長が抑制されました.
- ARF-BP1は直接p53をユビキチナートし,ARF媒介によるp53の安定化にはARF-BP1の無活性化が不可欠である.
結論:
- ARF-BP1は,ARFのp53-依存性およびp53-独立性腫瘍抑制機能の両方の重要なメディエーターです.
- ARF-BP1の二重な役割は,p53ステータスに関係なく,様々ながんの潜在的な治療標的であることを示唆しています.
関連する概念動画
Long-patch Base Excision Repair
6.3K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
6.3K
Abnormal Proliferation
4.0K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
mTOR Signaling and Cancer Progression
3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.6K
Receptor Downregulation in MVBs
2.0K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.0K
MAPK Signaling Cascades
7.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
PI3K/mTOR/AKT Signaling Pathway
5.2K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.2K


